Form 4 for DFTX Definium Therapeutics, Inc.

Accepted 2022-03-14 00:00:00 ET · period of report 2022-02-10 · accession 0001209191-22-018614 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
D	2022-03-14	2022-02-10	DFTX	Liao Carrie	VP, Ctrl, Acct Principal	A - Grant	$0.00	+403.4K	403.4K	New	$0
D	2022-03-14	2022-02-10	DFTX	Liao Carrie	VP, Ctrl, Acct Principal	A - Grant	$0.00	+524.5K	524.5K	New	$0

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Subordinate Voting Shares	2022-02-10	A	A	403,430	$0.00	403,430	D	—	—	(F1) Grant of 403,430 restricted stock units ("RSUs") on February 10, 2022. Each RSU represents a contingent right to receive one subordinate voting share of the Issuer. 25% of the RSUs will vest on October 21, 2022; the remaining RSUs granted will vest with 1/48th of the total shares vesting at the end of each month thereafter for the succeeding 36 months, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date.
2	Derivative	Stock Option (Right to Buy)	2022-02-10	A	A	524,450	$0.00	524,450	D	$1.34 · — to 2027-02-09	524,450 Subordinate Voting Shares	(F2) The option grant has an exercise price of $1.71 Canadian Dollars. This represents the exercise price in United States Dollars. (F3) 25% of the shares underlying the option shall vest and become exercisable on October 21, 2022; the remaining shares underlying the option shall vest and become exercisable with 1/48th of the total shares vesting at the end of each month thereafter for the succeeding 36 months, subject to the Reporting Person providing continuous service to the Issuer on each such vesting date.